Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04614363 · ClinicalTrials.gov registry record · Phase 1
68 Ga-PSMA for High Risk Prostate Cancer
A Phase 1 study, sponsored by The Methodist Hospital Research Institute.
- Completed
- Registry status
- Phase 1
- Development phase
- 80
- Enrollment target
NCT04614363 is a Phase 1 study that has completed, run by The Methodist Hospital Research Institute. The registered enrollment target is 80 participants.
The verdict
NCT04614363, a Phase 1 study, has completed, sponsored by The Methodist Hospital Research Institute.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 80 participants
- Enrollment target
Study Summary
This is a prospective, single-center, open-label pilot study of 68GA-PSMA-11 given at a single time prior to PET/CT imaging in men with localized high risk prostate cancer or biochemical recurrence. The imaging agent (68 Ga-PSMA 11 will be administered on an outpatient basis. It will be administered prior to the PET/CT imaging. The objective is to evaluate the distribution of 68GA-PSMA-11 in tissues and to determine if this alters the planned clinical management.
Interventions
- DRUG 68Ga-PSMA
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 80 participants |
| Start Date | 2020-10-13 |
| Est. Completion | 2023-04-25 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04614363
The ClinicalTrials.gov registry entry for NCT04614363 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 80 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is The Methodist Hospital Research Institute, which has 126 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which 68Ga-PSMA is the first listed.
NCT04614363 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04614363 about?
NCT04614363 is a clinical study titled "68 Ga-PSMA for High Risk Prostate Cancer". This is a prospective, single-center, open-label pilot study of 68GA-PSMA-11 given at a single time prior to PET/CT imaging in men with localized high risk prostate cancer or biochemical recurrence. The imaging agent (68 Ga-PSMA 11 will be administered on an outpatient basis. It will be administered...
What is the current status of trial NCT04614363?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 80 participants. The study started on 2020-10-13. Estimated completion is 2023-04-25.
What interventions are being tested in trial NCT04614363?
The interventions under investigation include: 68Ga-PSMA (DRUG).
Who is sponsoring clinical trial NCT04614363?
This trial is sponsored by The Methodist Hospital Research Institute, which has 126 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.